Ildong Pharmaceutical saw the highest growth of 0.99% in patent filings in June and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.35% and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Ildong Pharmaceutical’s patent filings and grants. Buy the databook here.
Ildong Pharmaceutical has been focused on protecting inventions in South Korea(KR) with three publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 50% of filings. The South Korea(KR), World Intellectual Property Organization(WIPO), United States(US), and European Patent Office(EPO) patent Office are among the top ten patent offices where Ildong Pharmaceutical is filings its patents. Among the top granted patent authorities, Ildong Pharmaceutical has 50% of its grants in United States(US) and 50% in Australia(AU).
Roche could be the strongest competitor for Ildong Pharmaceutical
Patents related to climate change lead Ildong Pharmaceutical's portfolio
Ildong Pharmaceutical has the highest number of patents in climate change.in Q2 2024.
Manufacturing/industrial related patents lead Ildong Pharmaceutical portfolio followed by rheumatoid arthritis, and asthma
Ildong Pharmaceutical has highest number of patents in manufacturing/industrial followed by rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (copd), and cystic fibrosis.
For comprehensive analysis of Ildong Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.